These results have to be interpreted with caution, as 19 of the total 62 patients (31%) had ALK-positive ALCL, a subentity with a much better prognosis than all other PTCL entities. The gene discussed is ALK; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.